Table 2.
The changes comparison of clinical characteristics before and after treatment in three groups (mean ± S.D.).
| Variable | TZQ Group (n=15) | Placebo Group (n=15) | Acarbose Group (n=16) | |||
|---|---|---|---|---|---|---|
| Before treatment | After treatment | Before treatment | After treatment | Before treatment | After treatment | |
| BMI (kg/m2) | 26.99±3.17 | 25.41±3.44 | 28.56±3.87 | 28.53±3.44 | 25.90±2.27 | 25.69±2.33 |
| Waistline (cm) | 95.43±11.24 | 92.77±10.29 | 100.23±8.36 | 100.60±8.29 | 94.87±8.44 | 93.63±7.74 |
| HbA1c (%) | 7.64±0.81 | 7.52±1.18 | 7.59±1.03 | 7.67±0.74 | 7.25±0.79 | 7.16±0.92 |
| FINS (mIU/L) | 16.64±8.65 | 14.28±8.29 | 15.00±7.07 | 15.73±7.77 | 15.10±14.57 | 10.42±4.97 △ |
| FBG (mmol/L) | 7.44±1.17 | 7.85±2.11 | 7.75±1.07 | 7.98±1.43 | 7.62±1.17 | 7.27±1.22 |
| OGTT2hBG (mmol/L) | 13.96±4.02 | 13.72±4.89 | 13.76±3.15 | 13.90±4.65 | 13.91±4.68 | 12.03±4.30 ∗△ |
| TG (mmol/L) | 1.52±0.61 | 1.88±1.51 | 2.06±1.05 | 2.17±1.24 | 2.35±1.38 | 1.81±1.18 ∗ |
| TC (mmol/L) | 4.92±0.70 | 4.99±0.93 | 4.87±0.82 | 4.95±1.05 | 4.74±0.78 | 4.56±0.90 |
| LDL (mmol/L) | 2.86±0.52 | 2.91±0.70 | 2.87±0.61 | 2.85±0.79 | 2.59±0.63 | 2.52±0.73 |
| HDL (mmol/L) | 1.38±0.39 | 1.30±0.40 | 1.17±0.25 | 1.17±0.30 | 1.22±0.35 | 1.24±0.40 |
Note: data were analyzed using paired t-test or covariance analysis. ∗p< 0.05 (compared with the same group before treatment, paired t-test), △p < 0.05 (compared with placebo group, covariance analysis). FBG: fasting blood glucose; OGTT 2hBG: oral glucose tolerance test 2 h blood glucose; HbA1c: glycosylated hemoglobin; BMI: body mass index; TC: total cholesterol; TG: triglyceride; HDL: high-density lipoprotein cholesterol; LDL: low-density lipoprotein cholesterol.